Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
Christiane Querfeld(City Of Hope National Medical Center), John A. Thompson(Fred Hutch Cancer Center), Matthew H. Taylor(Providence Portland Medical Center), Jennifer DeSimone(Inova Health System), Jasmine Zain(City Of Hope National Medical Center), Andrei R. Shustov(Fred Hutch Cancer Center), Carolyn Johns(Oregon Health & Science University), Sue McCann(University of Pittsburgh Medical Center), Gloria H. Y. Lin(Trillium Therapeutics (Canada)), Penka S. Petrova(Trillium Therapeutics (Canada)), Robert A. Uger(Trillium Therapeutics (Canada)), Naomi Molloy(Trillium Therapeutics (Canada)), Yaping Shou(Trillium Therapeutics (Canada)), Oleg E. Akilov(University of Pittsburgh Medical Center)
Cited by 75
Abstract
Related Papers
No related papers found
Powered by citation graph analysis